Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 999
Rating:

Prof Barbara Burtness - Yale Cancer Center, New Haven, USA

Prof Barbara Burtness speaks with ecancer at ESMO 2018 in Munich about results from a phase III study of pembrolizumab as mono therapy and in combination with EXTREME chemotherapy.

She describes the scoring system through which PD-L1 expression was ranked, with mono therapy improving survival in both PD-L1 positive populations over chemotherapy.

Prof Burtness notes toxicity profiles compared to the chemotherapy course, and that the combination was utilised in an all-comers population, meaning a direct comparison of arms is not wholly reflective of any superior treatment schedule.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation